Rogerio Vivaldi Coelho, M.D., M.B.A., has served as our President and Chief Executive Officer and as a member of our board of directors since 2018. Prior to joining Sigilon, Dr. Vivaldi served as Executive Vice President and Chief Global Therapeutics Officer at Bioverativ Inc. from 2016 until it was acquired by Sanofi in 2018, and served as Chief Commercial Officer at Spark Therapeutics between 2014 and 2016. Before that he led Genzyme’s rare disease business as President of both the rare disease business and the renal & endocrine group, as well as Senior Vice President and General Manager of Genzyme’s Latin America Group during his 20-year tenure at Genzyme. Dr. Vivaldi serves on the Board of Directors of Crinetics Pharmaceuticals, Inc. Dr. Vivaldi holds his medical degree from the Universidade do Rio de Janeiro. He completed a residency in endocrinology at the Universidade do Estado do Rio de Janeiro and a fellowship at Mount Sinai Hospital Center in New York in the department of genetics, focusing on Gaucher disease. Dr. Vivaldi holds an M.B.A. degree from COPPEAD, Universidade Federal do Rio de Janeiro.

Douglas Cole, M.D., has served as a member of our Board of Directors since 2016. Dr. Cole joined Flagship Pioneering, which conceives, creates, resources and develops first-in-category bioplatform companies, in 2001, and is currently a Managing Partner focused on life science investments. Dr. Cole currently serves on the Board of Directors of Denali Therapeutics, Foghorn Therapeutics, Sana Biotechnology, each of which is a public biotechnology company, and on the boards of directors of a number of private companies. In the past five years, Dr. Cole also served on the board of directors of Quanterix Corporation, a public life sciences company. Dr. Cole received his M.D. from the University of Pennsylvania School of Medicine and his A.B. in English from Dartmouth College.

John Cox has served as a member of our Board of Directors since 2019. Mr. Cox served as the Chief Executive Officer of Repertoire Immune Medicines from 2019 to November 2022, and was also the Chief Executive Officer of Bioverativ Inc. from 2017 until 2019, which he built, grew, and led until its successful acquisition by Sanofi S.A. Previously, Mr. Cox was Executive Vice President, Global Commercial & Technical Operations at Biogen Inc. from 2016 until 2017, where he was a member of the leadership team and was globally responsible for all aspects of an $11 billion commercial operation, as well as technical development and all drug supply. Prior to that, he served as Executive Vice President of Pharmaceutical Operations & Technology at Biogen Inc. from 2015 until 2016, in which he oversaw the company’s production facilities, supply chain operations, technical development, quality and engineering across the globe. He also was responsible for the creation of the company’s biosimilar business, including its successful commercialization in Europe. Mr. Cox holds an M.B.A. from the University of Michigan, an M.S. in cell biology from California State University and a B.S. in biology from Arizona State University.

Stephen Oesterle, M.D., has served as a member of our Board of Directors since 2016. Dr. Oesterle is a consultant, advising private equity and operating companies in the healthcare industry. From 2002 to 2015, he served as a member of the Executive Committee of Medtronic plc, a global medical technology, services and solutions company, amd as Medtronic plc’s Senior Vice President, Medicine and Technology. Previously, he served as an Associate Professor of Medicine and Director of Invasive Cardiology Services at Massachusetts General Hospital from 1998 to 2002, Stanford University Medical Center from 1992 to 1998, and Georgetown University Medical Center from 1991 to 1992. Dr. Oesterle has served as a member of the Board of Directors of Baxter International Inc. since 2017, Peijia Medical Limited since 2020, and Paragon28 since 2021. He also served as a director of REVA Medical, Inc. from February 2018 to May 2019 and HeartWare International, Inc. from January 2016 to November 2016, prior to Medtronic plc’s acquisition of HeartWare International, Inc. He currently serves on private boards of SHL Medical since 2020, CeramTec since 2022 and Alcyone since 2017.

Kavita Patel, M.D., has served as a member of our Board of Directors since 2020. Dr. Kavita Patel is a practicing physician in Washington, D.C., and was a Nonresident Fellow at the Brookings Institution, where her research and reports focused on patient-centered care, payment and delivery systems and health reform. She previously served in the Obama Administration as Director of Policy for the Office of Intergovernmental Affairs and Public Engagement in the White House. She also served as a policy analyst and aide to the late Senator Edward Kennedy. As Deputy Staff Director on Health, she was part of the senior staff of the Health, Education, Labor and Pensions (HELP) Committee under Senator Kennedy’s leadership. Dr. Patel also served as the Managing Director of Clinical Transformation at the Center for Health Policy at the Brookings Institution and Vice President of Payer and Provider Strategy at Johns Hopkins Health System. Dr. Patel currently serves on the Board of Directors of SelectQuote, Inc. Dr. Patel serves on the board of several non-profit organizations, including Dignity Healthcare and SSM Healthcare. She earned her M.D. from the University of Texas Health Science Center and her M.S.H.S. from the University of California, Los Angeles.

Robert R. Ruffolo, Jr., Ph.D., has served as a member of our Board of Directors since 2016. He served as the President of Research and Development and as Corporate Senior Vice President of Wyeth Pharmaceuticals from 2002 through 2008. In these roles, he managed an R&D organization of 9,000 scientists with an annual budget in excess of $3 billion. From 2000 to 2002, he served as an Executive Vice President at Wyeth Pharmaceuticals, where he was responsible for Pharmaceutical Research and Development. Prior to joining Wyeth Pharmaceuticals, Dr. Ruffolo spent 17 years at SmithKline Beecham Pharmaceuticals plc (now GlaxoSmithKline plc), where he was Senior Vice President and Director of Biological Sciences, Worldwide from 1984 to 2000. Before joining SmithKline Beecham Pharmaceuticals plc, Dr. Ruffolo spent six years at Eli Lilly and Company from 1978 to 1984, where he was a Senior Pharmacologist. Dr. Ruffolo currently serves on the Boards of Directors of Aridis Pharmaceuticals, Inc. and several private companies. He received his B.S. in Pharmacy from The Ohio State University and his Ph.D. in Pharmacology from The Ohio State University.

Eric Shaff has served as a member of our Board of Directors since 2017. Mr. Shaff is President and Chief Executive Officer of Seres Therapeutics, Inc., a role that follows a series of leadership positions at Seres Therapeutics, Inc. beginning in 2014. Prior to Seres Therapeutics, Inc., Mr. Shaff worked at Momenta Pharmaceuticals, Inc. and Genzyme Corporation, where he served as global head of finance of Genzyme’s Rare Genetic Disease Division in addition to roles in corporate development and corporate Finance. Mr. Shaff has also worked in corporate finance at Pfizer Inc. and in investment banking with Broadview International LLC (now Jefferies Broadview). Mr. Shaff earned a B.A. from the University of Pennsylvania and holds an M.B.A. from the Johnson Graduate School of Management at Cornell University.

Daniel G. Anderson, Ph.D., a co-founder of Sigilon Therapeutics, is a leading researcher in the field of nanotherapeutics and biomaterials. He is appointed in the Department of Chemical Engineering, the Institute for Medical Engineering and Science, the Koch Institute for Integrative Cancer Research, and the Harvard-MIT Division of Health Science and Technology at MIT. Dr. Anderson received a B.A. in mathematics and biology from the University of California at Santa Cruz and a Ph.D. in molecular genetics from the University of California at Davis. Dr. Anderson’s work has resulted in the publication of over 400 papers, patents and patent applications. These advances have led to products that have been commercialized or are in clinical development, as well as to the foundation of companies in the pharmaceutical, biotechnology and consumer product spaces including CRISPR Therapeutics AG, Living Proof, Inc., Verseau Therapeutics, Inc. and Olivo Laboratories, LLC.

Robert Langer, Sc.D., a co-founder of Sigilon, is a David H. Koch Institute Professor at the Massachusetts Institute of Technology. Dr. Langer has served on the boards of directors of Abpro Corporation since 2016, Frequency Therapeutics, Inc. since 2016, Rubius Therapeutics, Inc. since 2014, Moderna, Inc. since 2010, and Lyra Therapeutics, Inc. since 2006. Dr. Langer has previously served on the boards of directors of Puretech Health plc, Momenta Pharmaceuticals, Inc., Wyeth Pharmaceuticals, Kala Pharmaceuticals, Inc., Fibrocell Science, Inc., and Millipore Corp. Dr. Langer holds a Sc.D. in Chemical Engineering from the Massachusetts Institute of Technology and a B.S. in Chemical Engineering from Cornell University.

José Oberholzer, M.D., is a scientific founder at Sigilon. He is a physician-scientist with a long track record in cell therapy. Dr. Oberholzer, brings a wealth of highly valuable islet encapsulation expertise to Sigilon. He is a researcher, surgeon and the director of the Charles O. Strickler Transplant Center at the University of Virginia. Previous to that he was a Professor of Surgery, Endocrinology and Diabetes, Bioengineering, and Chief of the Division of Transplantation at the University of Illinois at Chicago (UIC). Dr. Oberholzer graduated from the University of Zurich Medical School in Switzerland and obtained a master’s in health care management from Harvard University. He completed his surgical training at the University of Geneva (Switzerland), as well as at the University of Alberta in Edmonton (Canada), where he completed a fellowship in hepatobiliary and pancreatic surgery and transplantation. He was the Head of the Islet Transplant Program at the University of Geneva and the GRAGIL islet consortium from 1998 to 2002, completing a significant number of islet transplants. He has been heading UIC’s islet program since 2003.

Arturo Vegas, Ph.D., Scientific Founder, provided fundamental contributions to the development of new materials for cell encapsulation and cell-based therapies as a post-doctoral fellow in the MIT laboratories of Robert Langer and Daniel G. Anderson. He is currently the Peter Paul Career Development Professor at Boston University. Appointed in the Department of Chemistry, Dr. Vegas has an affiliation with the Department of Biomedical Engineering and is a core faculty member of both the Boston University Center for Molecular Discovery as well as the Boston University Nanotechnology Innovation Center. Dr. Vegas received his B.A. from Cornell University and a Ph.D. in Chemistry from Harvard University. His work has led to 10 patents both issued and pending. He was recently awarded a New Innovator Type 1 Diabetes Pathfinder Award by the NIH.

Omid Veiseh, Ph.D., Scientific Founder, has over a decade of experience developing biotechnologies for clinical application. The transformative research discoveries he made as a postdoctoral research fellow helped catalyze the launch of Sigilon. Through grants from the Juvenile Diabetes Research Foundation and the Department of Defense, Dr. Veiseh worked to develop a bioartificial pancreas for the treatment of patients afflicted with type 1 diabetes. Dr. Veiseh developed a high-throughput pipeline for the synthesis and evaluation of material formulations that are able to resist foreign body reactions. These formulations were used to develop novel biomaterials for enhanced biocompatibility. The results lay the groundwork for encapsulated transplanted cells for delivery of biotherapeutics. In 2017, he will join the faculty at Rice University as an Assistant Professor of Bioengineering. Dr. Veiseh holds a Ph.D. from the University of Washington. He has authored or co-authored more than 50 peer-reviewed publications and is an inventor on 20 pending or awarded patents.

Daniel G. Anderson, Ph.D., a co-founder of Sigilon Therapeutics, is a leading researcher in the field of nanotherapeutics and biomaterials. He is appointed in the Department of Chemical Engineering, the Institute for Medical Engineering and Science, the Koch Institute for Integrative Cancer Research, and the Harvard-MIT Division of Health Science and Technology at MIT. Dr. Anderson received a B.A. in mathematics and biology from the University of California at Santa Cruz and a Ph.D. in molecular genetics from the University of California at Davis. Dr. Anderson’s work has resulted in the publication of over 400 papers, patents and patent applications. These advances have led to products that have been commercialized or are in clinical development, as well as to the foundation of companies in the pharmaceutical, biotechnology and consumer product spaces including CRISPR Therapeutics AG, Living Proof, Inc., Verseau Therapeutics, Inc. and Olivo Laboratories, LLC.

Constance Cepko, Ph.D., is Professor of Genetics and Neuroscience and Co-Director of the Leder Human Biology and Translational Medicine Program at Harvard Medical School. Her laboratory addresses questions regarding mechanisms of cell fate determination and has been developing gene therapy to address genetic forms of blindness. Dr. Cepko serves on the Scientific Advisory Boards of Permeon Biologics, Advanced Cell Technology and GenSight Biologics. Dr. Cepko is a member of American Academy of Arts and Sciences and member of the National Academy of Sciences.

Robert Langer, Sc.D., a co-founder of Sigilon, is a David H. Koch Institute Professor at the Massachusetts Institute of Technology. Dr. Langer has served on the boards of directors of Abpro Corporation since 2016, Frequency Therapeutics, Inc. since 2016, Rubius Therapeutics, Inc. since 2014, Moderna, Inc. since 2010, and Lyra Therapeutics, Inc. since 2006. Dr. Langer has previously served on the boards of directors of Puretech Health plc, Momenta Pharmaceuticals, Inc., Wyeth Pharmaceuticals, Kala Pharmaceuticals, Inc., Fibrocell Science, Inc., and Millipore Corp. Dr. Langer holds a Sc.D. in Chemical Engineering from the Massachusetts Institute of Technology and a B.S. in Chemical Engineering from Cornell University.

Ulrik B. Nielsen, Ph.D., is co-founder and CEO of Tidal Therapeutics, a company developing nucleotide-based therapeutics He was previously a co-founder, President and CEO of Torque Therapeutics from 2015 until 2018. Prior to Torque, Dr. Nielsen was co-founder and Chief Scientific Officer of Merrimack (NASDAQ: MACK) until 2015. Dr. Nielsen also serves on the Board of Directors for Alloy, Merrimack and North Therapeutics. He trained at the University of California, San Francisco, and MIT, and holds a Ph.D. in molecular biology from the University of Copenhagen.

Michael Rosenblatt, M.D., serves as the Chief Medical Officer of Flagship Pioneering. Prior to this role, Dr. Rosenblatt was the Executive Vice President and Chief Medical Officer for Merck from 2009 until 2016. He also served as Dean of Tufts University School of Medicine, and held appointments as the Robert Ebert Professor of Molecular Medicine and then George R. Minot Professor of Medicine at Harvard Medical School. He was a scientific founder of ProScript, the company that discovered bortezomib (Velcade), now Millennium Pharmaceutical’s drug for multiple myeloma and other malignancies, and Radius Pharmaceuticals, a women’s health company. Dr. Rosenblatt is the recipient of the Fuller Albright Award for his work on parathyroid hormone and the Vincent du Vigneaud Award in peptide chemistry and biology, and the Chairman’s Award from Merck. He serves as a member of the Board of Directors for Ferring Pharmaceuticals (U.S. Division), Rubius Therapeutics, Brooks Automation and several early stage biotech companies. Dr. Rosenblatt received his undergraduate degree summa cum laude from Columbia and his M.D. magna cum laude from Harvard. His internship, residency and endocrinology training were all at the Massachusetts General Hospital.